147 related articles for article (PubMed ID: 10949161)
1. Structural differences of matrix metalloproteinases. Homology modeling and energy minimization of enzyme-substrate complexes.
Terp GE; Christensen IT; Jørgensen FS
J Biomol Struct Dyn; 2000 Jun; 17(6):933-46. PubMed ID: 10949161
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of the stromelysin catalytic domain at 2.0 A resolution: inhibitor-induced conformational changes.
Chen L; Rydel TJ; Gu F; Dunaway CM; Pikul S; Dunham KM; Barnett BL
J Mol Biol; 1999 Oct; 293(3):545-57. PubMed ID: 10543949
[TBL] [Abstract][Full Text] [Related]
3. Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach.
Terp GE; Cruciani G; Christensen IT; Jørgensen FS
J Med Chem; 2002 Jun; 45(13):2675-84. PubMed ID: 12061871
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor.
Nar H; Werle K; Bauer MM; Dollinger H; Jung B
J Mol Biol; 2001 Sep; 312(4):743-51. PubMed ID: 11575929
[TBL] [Abstract][Full Text] [Related]
5. Structure of recombinant mouse collagenase-3 (MMP-13).
Botos I; Meyer E; Swanson SM; Lemaître V; Eeckhout Y; Meyer EF
J Mol Biol; 1999 Oct; 292(4):837-44. PubMed ID: 10525409
[TBL] [Abstract][Full Text] [Related]
6. Domain-selective ligand-binding modes and atomic level pharmacophore refinement in angiotensin I converting enzyme (ACE) inhibitors.
Tzakos AG; Gerothanassis IP
Chembiochem; 2005 Jun; 6(6):1089-103. PubMed ID: 15883972
[TBL] [Abstract][Full Text] [Related]
7. Screening of matrix metalloproteinases available from the protein data bank: insights into biological functions, domain organization, and zinc binding groups.
Nicolotti O; Miscioscia TF; Leonetti F; Muncipinto G; Carotti A
J Chem Inf Model; 2007; 47(6):2439-48. PubMed ID: 17958346
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor.
Fernandez-Catalan C; Bode W; Huber R; Turk D; Calvete JJ; Lichte A; Tschesche H; Maskos K
EMBO J; 1998 Sep; 17(17):5238-48. PubMed ID: 9724659
[TBL] [Abstract][Full Text] [Related]
9. Molecular dynamics simulations of matrix metalloproteinase 2: role of the structural metal ions.
Díaz N; Suarez D
Biochemistry; 2007 Aug; 46(31):8943-52. PubMed ID: 17616173
[TBL] [Abstract][Full Text] [Related]
10. Potent "clicked" MMP2 inhibitors: synthesis, molecular modeling and biological exploration.
Zapico JM; Serra P; García-Sanmartín J; Filipiak K; Carbajo RJ; Schott AK; Pineda-Lucena A; Martínez A; Martín-Santamaría S; de Pascual-Teresa B; Ramos A
Org Biomol Chem; 2011 Jun; 9(12):4587-99. PubMed ID: 21552627
[TBL] [Abstract][Full Text] [Related]
11. N-Hydroxyurea as zinc binding group in matrix metalloproteinase inhibition: mode of binding in a complex with MMP-8.
Campestre C; Agamennone M; Tortorella P; Preziuso S; Biasone A; Gavuzzo E; Pochetti G; Mazza F; Hiller O; Tschesche H; Consalvi V; Gallina C
Bioorg Med Chem Lett; 2006 Jan; 16(1):20-4. PubMed ID: 16242329
[TBL] [Abstract][Full Text] [Related]
12. Designing inhibitors of the metalloproteinase superfamily: comparative analysis of representative structures.
Dhanaraj V; Ye QZ; Johnson LL; Hupe DJ; Ortwine DF; Dunbar JB; Rubin JR; Pavlovsky A; Humblet C; Blundell TL
Drug Des Discov; 1996 Apr; 13(3-4):3-14. PubMed ID: 8874040
[TBL] [Abstract][Full Text] [Related]
13. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor.
Rowsell S; Hawtin P; Minshull CA; Jepson H; Brockbank SM; Barratt DG; Slater AM; McPheat WL; Waterson D; Henney AM; Pauptit RA
J Mol Biol; 2002 May; 319(1):173-81. PubMed ID: 12051944
[TBL] [Abstract][Full Text] [Related]
14. Understanding the P1' specificity of the matrix metalloproteinases: effect of S1' pocket mutations in matrilysin and stromelysin-1.
Welch AR; Holman CM; Huber M; Brenner MC; Browner MF; Van Wart HE
Biochemistry; 1996 Aug; 35(31):10103-9. PubMed ID: 8756473
[TBL] [Abstract][Full Text] [Related]
15. Quantum chemical study on the coordination environment of the catalytic zinc ion in matrix metalloproteinases.
Díaz N; Suarez D; Sordo TL
J Phys Chem B; 2006 Nov; 110(47):24222-30. PubMed ID: 17125395
[TBL] [Abstract][Full Text] [Related]
16. Refined 2.0 A X-ray crystal structure of the snake venom zinc-endopeptidase adamalysin II. Primary and tertiary structure determination, refinement, molecular structure and comparison with astacin, collagenase and thermolysin.
Gomis-Rüth FX; Kress LF; Kellermann J; Mayr I; Lee X; Huber R; Bode W
J Mol Biol; 1994 Jun; 239(4):513-44. PubMed ID: 8006965
[TBL] [Abstract][Full Text] [Related]
17. Crystal structures of acutolysin A, a three-disulfide hemorrhagic zinc metalloproteinase from the snake venom of Agkistrodon acutus.
Gong W; Zhu X; Liu S; Teng M; Niu L
J Mol Biol; 1998 Oct; 283(3):657-68. PubMed ID: 9784374
[TBL] [Abstract][Full Text] [Related]
18. Design in silico, synthesis and binding evaluation of a carbohydrate-based scaffold for structurally novel inhibitors of matrix metalloproteinases.
Fragai M; Nativi C; Richichi B; Venturi C
Chembiochem; 2005 Aug; 6(8):1345-9. PubMed ID: 15977273
[No Abstract] [Full Text] [Related]
19. Crystal structure of the stromelysin-3 (MMP-11) catalytic domain complexed with a phosphinic inhibitor mimicking the transition-state.
Gall AL; Ruff M; Kannan R; Cuniasse P; Yiotakis A; Dive V; Rio MC; Basset P; Moras D
J Mol Biol; 2001 Mar; 307(2):577-86. PubMed ID: 11254383
[TBL] [Abstract][Full Text] [Related]
20. Crystal structures of MMPs in complex with physiological and pharmacological inhibitors.
Maskos K
Biochimie; 2005; 87(3-4):249-63. PubMed ID: 15781312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
